Bacterin Launches OsteoSponge Subchondral Bone Filler

Bacterin, a Belgrade, Mont.-based bone graft developer, has launched the OsteoSponge for use to replace a damaged subchondral bone, according to a company news release.

Advertisement

The OsteoSponge is approved for use as a subchondral bone void filler by the FDA. The product is an acellular matrix scaffold made from donated human bone that replaces the patient’s damaged bone.

The device, which is used during a minimally invasive procedure, is designed to allow the surgeon to incorporate the patient’s own stem cells or bioactive agents to accelerate tissue regeneration.

Read the release on OsteoSponge from Bacterin.

Read other coverage on orthopedic and spine devices:

– DePuy Mitek Launches Rotator Cuff Repair System & Radiofrequency Technology

– Lanx Launches Epic Anterior Thoracolumbar Plating System

– ArthroCare Receives FDA 510(k) Clearance on Spartan 5.5 Needle Anchor

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • Since March 25, there have been two key developments in lawsuits involving spine medtech companies. 1. The U.S. Court of…

  • The highest-paid CFOs at spine and orthopedic medtech companies saw total compensation reaching in the mid-single digits and beyond. Here…

Advertisement

Comments are closed.